![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
880kB |
Preview |
PDF (Supplemental Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
286kB |
| Item Type: | Article |
|---|---|
| Title: | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
| Creators Name: | Kraus, S., Klassen, P., Kircher, M., Dierks, A., Habringer, S., Gäble, A., Kortüm, K.M., Weinhold, N., Ademaj-Kospiri, V., Werner, R.A., Schirbel, A., Buck, A.K., Herhaus, P., Wester, H.J., Rosenwald, A., Weber, W.A., Einsele, H., Keller, U., Rasche, L. and Lapa, C. |
| Abstract: | Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. METHODS: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. RESULTS: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; (P<) 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 ((P<) 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75;P= 0.009). CONCLUSION: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted. |
| Keywords: | Multiple Myeloma, 68 Ga-Pentixafor-PET/CT, CXCR4, Molecular Imaging, Spleen |
| Source: | Theranostics |
| ISSN: | 1838-7640 |
| Publisher: | Ivyspring International Publisher |
| Volume: | 12 |
| Number: | 13 |
| Page Range: | 5986-5994 |
| Date: | 8 August 2022 |
| Official Publication: | https://doi.org/10.7150/thno.75847 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
